Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients
June 21, 2023 08:19 ET
|
Biomerica, Inc.
Patent Claims Describe a Novel System to Predict and Help Prevent Adverse Food Reactions Using Personal Medical DataThe Patent further describes Algorithms to help Determine Safety Levels of Food...
Global Gastrointestinal Partnering Analysis Report 2023: Deal Trends, Players and Financials for Over 480 Deals Signed Since 2016 by the World's Leading Life Science Companies
May 31, 2023 03:13 ET
|
Research and Markets
Dublin, May 31, 2023 (GLOBE NEWSWIRE) -- The "Global Gastrointestinal Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.Global...
Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).
April 17, 2023 07:47 ET
|
Biomerica, Inc.
Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United StatesClinical study results show patients who eliminated foods as determined by the inFoods® IBS test...
Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed
March 08, 2023 08:19 ET
|
Biomerica, Inc.
InFoods® IBS LDT validation testing at the CLIA Lab is completed and the product is now being offered commerciallyClinical trial data shows InFoods® IBS treatment diet significantly improved several...
Irritable Bowel Syndrome Pipeline Booms as 24+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
January 18, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Irritable Bowel Syndrome Pipeline Booms as 24+ Therapies Likely to Enter in the Treatment Domain | DelveInsight Irritable bowel syndrome (IBS) is a...
Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board
January 10, 2023 08:19 ET
|
Biomerica, Inc.
Dr. Lacy is the former co-Editor in Chief of the American Journal of Gastroenterology, the former Editor in Chief of Clinical and Translational Gastroenterology, and has served as the co-Chairman for...
Constipation Treatment Market is expected to generate a revenue of USD 29.04 Billion by 2028, Globally, at 6.77% CAGR: Verified Market Research®
December 13, 2022 11:30 ET
|
Verified Market Research
Jersey City, New Jersey, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Verified Market Research® recently published a report, “Constipation Treatment Market” By Disease Type (Chronic idiopathic constipation...
Global Gastrointestinal Partnering Report and Directory 2022: Trends by Year, Deal Type, Stage of Development, Technology Type and Therapeutic Indication
December 02, 2022 08:09 ET
|
Research and Markets
Dublin, Dec. 02, 2022 (GLOBE NEWSWIRE) -- The "Global Gastrointestinal Partnering 2015-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. The...
Biomerica InFoods® IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting
November 02, 2022 08:19 ET
|
Biomerica, Inc.
ACG Presidential Award Received for the InFoods® IBS Data Presented at the American College of Gastroenterology (ACG) Annual Scientific MeetingThe Presented Clinical Study Data Showed InFoods® IBS...
Irritable Bowel Syndrome Treatment Market Size is expected to reach at USD 4.7 Billion by 2030, registering a CAGR of 9.5%, Owing to Increasing Incidences of Gastrointestinal Disorders
October 03, 2022 09:48 ET
|
Acumen Research and Consulting
LOS ANGELES, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Global Irritable Bowel Syndrome Treatment Market Size accounted for USD 2.1 Billion in 2021 and is projected to achieve a market size of USD 4.7...